New York, NY -- (SBWIRE) -- 11/13/2017 -- In a recent clinical landmark, Rexahn Pharmaceuticals dosed its first patient in a Phase II pancreatic cancer study …
Over the last six months, Vertex was up 27.2% while Celgene was down 16.9% …
JUNO stock generated over 31.8% returns in the last four weeks ... Moreover, the revenue recognized under their Celgene Collaboration Agreement and Celgene CD19 License improved against the prior year period. Juno also controlled their …
Celgene (CELG) stock closed lower by 10.76% on Friday, after the company reported that it would terminate its Crohn’s disease studies. It was supposed to press on to another phase 3 clinical trial, but the latest data has caused it to …
Celgene turned in a brutal third-quarter earnings report, missing revenue forecasts and cutting its long-term profit outlook. Traders were woefully unhedged by several measures, leaving them vulnerable to feel the brunt of the stock's 20% drop. …
With the iShares Nasdaq Biotechnology Index (ETF) ( IBB) down almost 30% in the last year, it would seem that all large biotech stocks are presenting investment value, but that's not the case, since many of the losses are appropriate in this …
Celgene Corporation (NASDAQ: CELG) is a biopharmaceutical company that researches and develops drugs for treating inflammatory diseases and various types of cancer. Celgene's core drugs are Revlimid, which makes up 66% of sales, …
Even some of the biggest and best have things go wrong every now and then. Celgene (NASDAQ: CELG) has been the best-performing biotech stock over the last five years among big biotechs with market caps over $50 billion. And now, …
Celgene (NASDAQ: CELG) stock has been in my investment portfolio since 2013. I enjoyed a couple of great years with the biotech stock performing really well. Over the past couple of years, however, Celgene hasn't generated high …
Celgene Corp. (NASDAQ: CELG) has decided to join the stock split game. Stock splits do not create any fundamental change on the surface, but the problem that Celgene has faced is that the run up in shares has lowered its average …